{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-011155","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2025-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.273109+00:00","generated_at":"2026-05-26T23:23:12.619192+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Voyager delays SOD1 ALS IND filing; switches payload after NHP data; cash runway to mid-2027","bullets":["VY9323 IND/CTA filing no longer expected mid-2025 due to need for alternate payload after 3-month NHP data.","Capsid unchanged; decision based on achieving desired product profile for SOD1 ALS gene therapy.","Other programs unaffected: Neurocrine GBA1 and Friedreich’s ataxia IND filings still on track for 2025.","Tau silencing program VY1706 IND expected in 2026; preclinical activity levels achieved.","Cash and equivalents plus collaboration reimbursements fund operations into mid-2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-011155","json":"https://secwatch.observer/filing/0001104659-25-011155.json","markdown":"https://secwatch.observer/filing/0001104659-25-011155.md","text":"https://secwatch.observer/filing/0001104659-25-011155.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000110465925011155/0001104659-25-011155-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000110465925011155/tm256087d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:23:12.619192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}